Moleculin Biotech Files 8-K on Shareholder Votes

Ticker: MBRX · Form: 8-K · Filed: May 9, 2025 · CIK: 1659617

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, sec-filing

Related Tickers: MBRX

TL;DR

Moleculin Biotech (MBRX) filed an 8-K on May 9th regarding shareholder votes. Standard corporate update.

AI Summary

Moleculin Biotech, Inc. filed an 8-K on May 9, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its state of incorporation (Delaware) and its principal executive offices located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.

Why It Matters

This filing provides an update on corporate governance matters, specifically concerning votes by Moleculin Biotech's security holders, which can impact shareholder rights and company direction.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure regarding shareholder votes and does not appear to contain material non-public information that would immediately impact the stock price.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that the 8-K is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and is reporting on 'Submission of Matters to a Vote of Security Holders'. However, the specific details of these matters are not provided in the excerpt.

When was the earliest event reported in this filing?

The date of the earliest event reported is May 9, 2025.

What is Moleculin Biotech, Inc.'s state of incorporation?

Moleculin Biotech, Inc. is incorporated in Delaware.

Where are Moleculin Biotech, Inc.'s principal executive offices located?

The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.

What is the company's telephone number?

The registrant's telephone number is (713) 300-5160.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 9, 2025 regarding Moleculin Biotech, Inc. (MBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing